These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30802475)

  • 1. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A.
    Wang K; Zhou L; Zhang X; Song C; Chen T; Li J; Zheng M; Wang Y; Zheng Q; Zheng Z; Yu H; Wu T; Gu Y; Zhang J; Zhao Q; Li S; Xia N
    Antiviral Res; 2019 Apr; 164():154-161. PubMed ID: 30802475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
    Zhang X; Wei M; Sun G; Wang X; Li M; Lin Z; Li Z; Li Y; Fang M; Zhang J; Li S; Xia N; Zhao Q
    Vaccine; 2016 Nov; 34(48):5871-5877. PubMed ID: 27793484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy.
    Sridhar S; Situ J; Cai JP; Yip CC; Wu S; Zhang AJ; Wen L; Chew NF; Chan WM; Poon RW; Chan JF; Tsang DN; Chen H; Xia NS; Yuen KY
    J Hepatol; 2021 Jun; 74(6):1315-1324. PubMed ID: 33845058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.
    Li SW; Zhang J; Li YM; Ou SH; Huang GY; He ZQ; Ge SX; Xian YL; Pang SQ; Ng MH; Xia NS
    Vaccine; 2005 Apr; 23(22):2893-901. PubMed ID: 15780738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific memory B cell response and participation of CD4
    Kulkarni SP; Thanapati S; Arankalle VA; Tripathy AS
    Vaccine; 2016 Nov; 34(48):5895-5902. PubMed ID: 27997340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion of C3d molecule with neutralization epitope(s) of hepatitis E virus enhances antibody avidity maturation and neutralizing activity following DNA immunization.
    Yang S; Wang C; Fang X; Zhai L; Dong C; Ding L; Meng J; Wang L
    Virus Res; 2010 Aug; 151(2):162-9. PubMed ID: 20451569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods.
    Yin X; Wang X; Zhang Z; Li Y; Lin Z; Pan H; Gu Y; Li S; Zhang J; Xia N; Zhao Q
    J Pharm Biomed Anal; 2020 Jan; 177():112880. PubMed ID: 31546137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes.
    Wei M; Zhang X; Yu H; Tang ZM; Wang K; Li Z; Zheng Z; Li S; Zhang J; Xia N; Zhao Q
    Vaccine; 2014 May; 32(24):2859-65. PubMed ID: 24662711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.
    Yu XY; Chen ZP; Wang SY; Pan HR; Wang ZF; Zhang QF; Shen LZ; Zheng XP; Yan CF; Lu M; Chen B; Zheng Y; Zhang J; Lv HK; Huang SJ
    Vaccine; 2019 Jul; 37(32):4581-4586. PubMed ID: 31262585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons from hepatitis E vaccine design.
    Li S; Zhang J; Xia N
    Curr Opin Virol; 2015 Apr; 11():130-6. PubMed ID: 25913817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and immunogenicity analysis of the combined vaccine against zoonotic hepatitis E and foot-and-mouth disease.
    Liu Z; Behloul N; Baha S; Wei W; Shi R; Meng J
    Vaccine; 2019 Oct; 37(46):6922-6930. PubMed ID: 31604580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a fully liquid aluminum phosphate adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in healthy Japanese children: A phase III, randomized, observer-blind, multicenter, parallel-group study.
    Togashi T; Mitsuya N; Kogawara O; Sumino S; Takanami Y; Sugizaki K
    Vaccine; 2016 Aug; 34(38):4635-4641. PubMed ID: 27265451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity difference between two hepatitis E vaccines derived from genotype 1 and 4.
    Wen J; Behloul N; Dai X; Dong C; Liang J; Zhang M; Shi C; Meng J
    Antiviral Res; 2016 Apr; 128():36-42. PubMed ID: 26850829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective efficacy in rhesus monkeys of a recombinant ORF2 protein from hepatitis E virus genotype 4.
    Huang WJ; Zhang HY; Harrison TJ; Lan HY; Huang GY; Wang YC
    Arch Virol; 2009; 154(3):481-8. PubMed ID: 19240977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of new hepatitis E vaccines.
    Cao Y; Bing Z; Guan S; Zhang Z; Wang X
    Hum Vaccin Immunother; 2018; 14(9):2254-2262. PubMed ID: 29708836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates.
    Ma H; Song X; Harrison TJ; Li R; Huang G; Zhang H; Kong W; Wang Y
    Arch Virol; 2009; 154(10):1641-8. PubMed ID: 19763777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope.
    Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.
    Caro-Aguilar I; Ottinger E; Hepler RW; Nahas DD; Wu C; Good MF; Batzloff M; Joyce JG; Heinrichs JH; Skinner JM
    Hum Vaccin Immunother; 2013 Mar; 9(3):488-96. PubMed ID: 23249976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.